Medical use of marijuana for a broad range of conditions is expanding rapidly in the US, but the future for this market is still uncertain, writes Harriet Kozak.
Before entering into risk-sharing agreements, manufacturers must understand the challenges and implications, writes Kimberly E. White.
Webinar Date/Time: Thursday, October 3, 2024 at 2pm EDT|11am PDT|7pm BST|8pm CEST
John Sattler offers some tips on engaging executive and professional recruiters.
If HEOR teams don’t clearly and concisely define themselves, their discipline, and their mission, they risk failure and irrelevance. A thoughtful communications program aimed at colleagues will win them due recognition of the value they bring, a say in key business decisions, and ongoing relevance.
is spectacular science enough to guarantee success for new medicines?
Abigail Bernardi explains how a better understanding of connections among practitioners on care teams helps sales reps build relationships while benefitting a company’s marketing efforts.
The GAIN Act creates a process for the Qualified Infectious Disease Product (QIDP) designation, which provides a range of incentives for developing antimicrobial therapies for combating resistant organisms. But while the program has been successful in driving innovation, commercial viability remains a question.
Mark Bouch, Stephen Bungay, and David Roblin outline how the technique of "mission command", a military approach to setting direction and executing strategy in the pharmaceutical industry, has developed over the last ten years.
Paul Meade and Mark Schoeman describe the determining factor driving effective relationships between medical science liaisons and key opinion leaders.
The Chinese government's “Healthy China” plan presents an unprecedented opportunity for the US healthcare industry and its investors, writes Steven Shill.
Innovation by itself won't solve the complex multichannel challenges pharmas face.
Groundbreaking treatment approaches call for innovative commercialization strategies.
Groundbreaking treatment approaches call for innovative commercialization strategies.
Groundbreaking treatment approaches call for innovative commercialization strategies.
Groundbreaking treatment approaches call for innovative commercialization strategies.
Darcee Strube offers an overview of the key issues and progress made in dermatology biologics.
With over 70 companies manufacturing immediate-release opioids in the United States, federal regulators may look to limit, or at least impose greater control over, marketing as a strategy to reduce the prescription, and more specifically, the improper and/or over-prescription of opioids.
With over 70 companies manufacturing immediate-release opioids in the United States, federal regulators may look to limit, or at least impose greater control over, marketing as a strategy to reduce the prescription, and more specifically, the improper and/or over-prescription of opioids.
In the search for effective and efficient ways to bridge the urban/rural divide, technological advances are offering more and more solutions.
This article discusses the best practices for transforming legacy approaches of managing data into modern ones capable of achieving the ambitious visions of pharmaceutical companies.
French independent pharma Servier Group, led by president Olivier Laureau, is uniquely positioned to capitalize on new opportunities for expansion and stay true to its R&D and patient-focused mission.
In Episode Three of the Syneos Health Dedicated Dialogue podcast series, we uncover how the proliferation of new digital health technologies, telemedicine and mobile nursing services are helping fuel novel clinical trials. These range from community-based studies, which are administered through PCPs, local health centers and outpatient facilities in lieu of academic research centers, to hybrid and fully virtual trials designed around patients in their homes, with or without a synthetic control arm replacing patients on placebos. Additionally, we share new insights about how trial sponsors discovering new ways to engage participants, enhance data capture and devise pathways to put patients at the center of clinical trials across the biopharmaceutical product development continuum.
Tracy Rockney and Rob Merrill talk about their free regulatory compliance and information platform MyIndago, and why they think the industry needs it now.